• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment.

作者信息

Robinson Philip C, Richards Duncan, Tanner Helen L, Feldmann Marc

机构信息

Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.

Metro North Hospital and Health Service, Brisbane, QLD, Australia.

出版信息

Lancet Rheumatol. 2020 Nov;2(11):e653-e655. doi: 10.1016/S2665-9913(20)30309-X. Epub 2020 Sep 5.

DOI:10.1016/S2665-9913(20)30309-X
PMID:33521660
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7832144/
Abstract
摘要

相似文献

1
Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment.越来越多的证据表明，在新冠病毒病治疗中，抗TNF治疗需要优先进行试验。
Lancet Rheumatol. 2020 Nov;2(11):e653-e655. doi: 10.1016/S2665-9913(20)30309-X. Epub 2020 Sep 5.
2
Why Rehabilitation must have priority during and after the COVID-19-pandemic: A position statement of the Global Rehabilitation Alliance.为什么康复治疗必须在 COVID-19 大流行期间和之后成为优先事项：全球康复联盟的立场声明。
J Rehabil Med. 2020 Jul 30;52(7):jrm00081. doi: 10.2340/16501977-2713.
3
Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial.抗血栓治疗改善新型冠状病毒肺炎并发症（ATTACC）：一项国际适应性贝叶斯随机对照试验的研究设计与方法
Clin Trials. 2020 Oct;17(5):491-500. doi: 10.1177/1740774520943846. Epub 2020 Aug 20.
4
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.英夫利昔单抗诱导治疗对肿瘤坏死因子拮抗剂治疗失败的克罗恩病患者的影响。
Gastroenterology. 2014 Sep;147(3):618-627.e3. doi: 10.1053/j.gastro.2014.05.008. Epub 2014 May 21.
5
It is unprecedented: trial management during the COVID-19 pandemic and beyond.这是前所未有的：COVID-19 大流行期间及之后的临床试验管理。
Trials. 2020 Sep 11;21(1):784. doi: 10.1186/s13063-020-04711-6.
6
Vitamin D Supplementation to Prevent COVID-19 Infections and Deaths-Accumulating Evidence from Epidemiological and Intervention Studies Calls for Immediate Action.维生素 D 补充剂预防 COVID-19 感染和死亡——来自流行病学和干预研究的累积证据呼吁立即采取行动。
Nutrients. 2021 Jan 28;13(2):411. doi: 10.3390/nu13020411.
7
Optimizing anti-TNF treatments in inflammatory bowel disease.优化炎症性肠病的抗 TNF 治疗。
Autoimmun Rev. 2014 Jan;13(1):24-30. doi: 10.1016/j.autrev.2013.06.002. Epub 2013 Jun 19.
8
The COVID-19 response must integrate people living with HIV needs in Sub-Saharan Africa: the case of Mali.应对新冠疫情必须兼顾撒哈拉以南非洲地区艾滋病毒感染者的需求：以马里为例。
Trop Med Health. 2020 Jun 3;48:41. doi: 10.1186/s41182-020-00228-5. eCollection 2020.
9
Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL).影响克罗恩病患者选择抗肿瘤坏死因子药物偏好因素的系统评估（CHOOSE TNF TRIAL）。
Inflamm Bowel Dis. 2012 Aug;18(8):1523-30. doi: 10.1002/ibd.21888. Epub 2011 Oct 10.
10
Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.抗 TNF-α 药物的作用机制分子 - 治疗性 TNF-α 拮抗剂的比较。
Cytokine. 2018 Jan;101:56-63. doi: 10.1016/j.cyto.2016.08.014. Epub 2016 Aug 24.

引用本文的文献

1
Secondary metabolites of Alternaria alternate appraisal of their SARS-CoV-2 inhibitory and anti-inflammatory potentials.链格孢的次生代谢产物：对其抑制SARS-CoV-2和抗炎潜力的评估
PLoS One. 2025 Jan 24;20(1):e0313616. doi: 10.1371/journal.pone.0313616. eCollection 2025.
2
The Impact of Infliximab on Hyperinflammation State in Hospitalized COVID-19 Patients: A Retrospective Study.英夫利昔单抗对住院 COVID-19 患者过度炎症状态的影响：一项回顾性研究。
Medicina (Kaunas). 2024 Oct 11;60(10):1670. doi: 10.3390/medicina60101670.
3
Network-based integrative multi-omics approach reveals biosignatures specific to COVID-19 disease phases.基于网络的整合多组学方法揭示了新冠病毒疾病不同阶段特有的生物标志物。
Front Mol Biosci. 2024 Jul 8;11:1393240. doi: 10.3389/fmolb.2024.1393240. eCollection 2024.
4
analysis of the impact of toxic metals on COVID-19 complications: molecular insights.分析有毒金属对 COVID-19 并发症的影响：分子层面的见解。
Arh Hig Rada Toksikol. 2024 Jun 29;75(2):102-109. doi: 10.2478/aiht-2024-75-3819. eCollection 2024 Jun 1.
5
A phosphodiesterase-4 inhibitor reduces lung inflammation and fibrosis in a hamster model of SARS-CoV-2 infection.一种磷酸二酯酶-4 抑制剂可减少 SARS-CoV-2 感染仓鼠模型中的肺部炎症和纤维化。
Front Immunol. 2023 Oct 2;14:1270414. doi: 10.3389/fimmu.2023.1270414. eCollection 2023.
6
SARS-CoV-2 mouse adaptation selects virulence mutations that cause TNF-driven age-dependent severe disease with human correlates.SARS-CoV-2 小鼠适应性选择毒力突变，导致 TNF 驱动的与人类相关的年龄依赖性严重疾病。
Proc Natl Acad Sci U S A. 2023 Aug 8;120(32):e2301689120. doi: 10.1073/pnas.2301689120. Epub 2023 Jul 31.
7
Prevalence and complication of COVID-19 in patients with ankylosing spondylitis (AS) and its relationship with TNF-a inhibitors.COVID-19 的患病率和并发症在强直性脊柱炎（AS）患者及其与 TNF-a 抑制剂的关系。
Immun Inflamm Dis. 2023 Jun;11(6):e915. doi: 10.1002/iid3.915.
8
Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome.评估 COVID-19 细胞因子风暴综合征患者中使用英夫利昔单抗/托珠单抗与托珠单抗的效果。
Sci Rep. 2023 Apr 20;13(1):6456. doi: 10.1038/s41598-023-33484-6.
9
Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries.银屑病、银屑病关节炎和中轴型脊柱关节炎患者 COVID-19 结局不良的相关特征：COVID-19 PsoProtect 和全球风湿病联盟医生报告登记处的数据。
Ann Rheum Dis. 2023 May;82(5):698-709. doi: 10.1136/ard-2022-223499. Epub 2023 Feb 14.
10
Carotenoids as potential inhibitors of TNFα in COVID-19 treatment.类胡萝卜素作为 COVID-19 治疗中 TNFα 的潜在抑制剂。
PLoS One. 2022 Dec 27;17(12):e0276538. doi: 10.1371/journal.pone.0276538. eCollection 2022.

本文引用的文献

1
An inflammatory cytokine signature predicts COVID-19 severity and survival.炎症细胞因子特征可预测 COVID-19 严重程度和存活情况。
Nat Med. 2020 Oct;26(10):1636-1643. doi: 10.1038/s41591-020-1051-9. Epub 2020 Aug 24.
2
SARS CoV-2 infection among patients using immunomodulatory therapies.使用免疫调节疗法的患者中的新型冠状病毒2型感染
Ann Rheum Dis. 2021 Feb;80(2):269-271. doi: 10.1136/annrheumdis-2020-218580. Epub 2020 Aug 5.
3
Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series.英夫利昔单抗治疗重症新型冠状病毒肺炎所致细胞因子风暴综合征伴器官衰竭——警示性病例系列
Crit Care. 2020 Jul 17;24(1):444. doi: 10.1186/s13054-020-03158-0.
4
Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19.COVID-19 和流感的免疫表型分析突出了 I 型干扰素在 COVID-19 重症发展中的作用。
Sci Immunol. 2020 Jul 10;5(49). doi: 10.1126/sciimmunol.abd1554.
5
Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds.英夫利昔单抗治疗重度溃疡性结肠炎及后续的新型冠状病毒肺炎：一石二鸟。
Gut. 2021 Mar;70(3):623-624. doi: 10.1136/gutjnl-2020-321760. Epub 2020 Jun 17.
6
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.风湿性疾病患者因 COVID-19 住院的相关特征：来自 COVID-19 全球风湿病联盟医生报告登记处的数据。
Ann Rheum Dis. 2020 Jul;79(7):859-866. doi: 10.1136/annrheumdis-2020-217871. Epub 2020 May 29.
7
Pediatric Crohn Disease and Multisystem Inflammatory Syndrome in Children (MIS-C) and COVID-19 Treated With Infliximab.儿童克罗恩病和儿童多系统炎症综合征（MIS-C）与 COVID-19 采用英夫利昔单抗治疗。
J Pediatr Gastroenterol Nutr. 2020 Aug;71(2):153-155. doi: 10.1097/MPG.0000000000002809.
8
Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.皮质类固醇，而不是 TNF 拮抗剂，与炎症性肠病患者 COVID-19 不良结局相关：来自国际登记处的结果。
Gastroenterology. 2020 Aug;159(2):481-491.e3. doi: 10.1053/j.gastro.2020.05.032. Epub 2020 May 18.
9
Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed.迫切需要开展针对新型冠状病毒肺炎的抗肿瘤坏死因子疗法试验。
Lancet. 2020 May 2;395(10234):1407-1409. doi: 10.1016/S0140-6736(20)30858-8. Epub 2020 Apr 9.
10
Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade.类风湿关节炎患者的炎症和促血栓形成生物标志物：肿瘤坏死因子-α阻断的作用
J Autoimmun. 2008 Sep;31(2):175-9. doi: 10.1016/j.jaut.2008.07.002. Epub 2008 Aug 15.